Journal article
Drug profile: Olcegepant, a non-peptide CGRP1 antagonist for migraine treatment
IDrugs : the investigational drugs journal, Vol.10(8), pp.566-574
2007
PMID: 17665333
Abstract
Olcegepant is the first potent and selective non-peptide antagonist of the calcitonin gene-related peptide 1 (CGRP1) receptor, a key modulator in neurogenic inflammatory pain. Under development by Boehringer Ingelheim GmbH, olcegepant is an intravenously formulated treatment for acute attacks of migraine. In preclinical studies, olcegepant attenuated arterial dilation induced by CGRP or electrical stimulation. In a phase II clinical trial, olcegepant reduced the severity of headache in 60% of migraine sufferers and met secondary endpoints including headache-free rate and rate of sustained response. Only mild-to-moderate transient adverse events were observed, with no adverse cardiovascular symptoms reported. The compound appears to be an effective anti-migraine medication that is well tolerated and does not display the vasoconstrictive effect that precludes the use of triptans and dihydroergotamine in certain patients. For the successful marketing of olcegepant, larger clinical trials and the development of an effective oral formulation will be necessary.
Details
- Title: Subtitle
- Drug profile: Olcegepant, a non-peptide CGRP1 antagonist for migraine treatment
- Creators
- Ana Recober - Department of Neurology, 2RCP, University of IowaAndrew F Russo - Department of Physiology and Biophysics, 5-432 BSB, University of Iowa
- Resource Type
- Journal article
- Publication Details
- IDrugs : the investigational drugs journal, Vol.10(8), pp.566-574
- PMID
- 17665333
- NLM abbreviation
- IDrugs
- ISSN
- 1369-7056
- eISSN
- 2040-3410
- Publisher
- THOMSON REUTERS (SCIENTIFIC) LTD; LONDON
- Number of pages
- 9
- Language
- English
- Date published
- 2007
- Academic Unit
- Neurology; Molecular Physiology and Biophysics; Iowa Neuroscience Institute; Craniofacial Anomalies Research Center
- Record Identifier
- 9984072080602771
Metrics
17 Record Views